Yun Zhi Polysaccharopeptide (PSP) and the General Aspects of Its Research

Abstract

This paper briefly introduces the general aspects of a new type biolobical response modifier—PSP. The production material of polysaccharopeptide (PSP) is the deep layer cultivated mycelia of Cov-1 strain of Yun Zhi isolated by the methol of water extraction and alcoholic precipitation. Its chemical components are protein-bound polysaccharides. After the analyses of (superscript 1) H, (superscript 13) C nuclear magentic resonance, GCMS on-line and HPLC analysis, it has been proved that the polysaccharopeptide contains Glc., Gla., Man., and Xy1. in addition to Ara. and Rahmose. In the polysaccharide of PSP, the main content is β1-3 glycosidic bond and it is different from that of Japanese Krestin (PSK). The pharmacology proves that PSP can obviously resist immune suppression caused by tumor-bearing or chemotherapy, prevent the atrophy of thymus, activate NK and LAK cells and incresse the contents of γ-interferon, IL-2, IL-6, etc. The toxicology proves that even administering 50-100 times the normal clinical dosage to patients, the toxicity of PSP is equivalent to that of ordinary drinking water, either in the cure of acute and chronic hepatitis, hereditary, reproductive and second generation teratogenic toxicity. PSP can obviously kill the SPS of lung cancer and SMMU-7721 of liver cancer cells and there is no obvious harm at all on V79 of lung cells and on GZG of liver cells. Through 485 cases of random double-blind clinical experiments, it has been proved that PSP can obviously improve the clinical symptoms of stomach, lung and esophagus cancer patients, lower the toxic and side effects of chemo- and radio-therapy and raise the life quality of patients. The total effective rate is 82.96%.